Get started
Author

Kate Hayes

Modulators of CFTR. Updates on clinical development and future directions
2021 · Emmanuelle Bardin, Alexandra Pastor, et al. · European Journal of Medicinal Chemistry · 72
PDF
Comparing accelerometer, pedometer and a questionnaire for measuring physical activity in bronchiectasis: a validity and feasibility study
2017 · B. O’Neill, S. M. McDonough, et al. · Respiratory Research · 69
PDF
Sedentary behaviour and physical activity in bronchiectasis: a cross-sectional study
2015 · Judy M Bradley, Jason J Wilson, et al. · BMC Pulmonary Medicine · 49
PDF
Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge
2021 · Agathe Lepissier, Charlotte Addy, et al. · Journal of Cystic Fibrosis · 28
Sweat Chloride Testing and Nasal Potential Difference (NPD) Are Primary Outcome Parameters in Treatment with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
2021 · Isabelle Sermet-Gaudelus, Thao Nguyen-Khoa, et al. · Journal of Personalized Medicine · 24
PDF
A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials
2019 · G. Taccetti, M. Denton, et al. · Journal of Cystic Fibrosis · 20
PDF
Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants
2022 · Anita Golec, Iwona Pranke, et al. · STAR Protocols · 17
PDF
Applying the Transtheoretical Model to Physical Activity Behavior in Individuals With Non-Cystic Fibrosis Bronchiectasis
2015 · Jason J Wilson, Alison Kirk, et al. · Respiratory Care · 16
PDF
Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures
2021 · Silke van Koningsbruggen-Rietschel, Fiona Dunlevy, et al. · Trials · 9
PDF
“Il faut continuer à poser des questions” patient reported outcome measures in cystic fibrosis: An anthropological perspective
2021 · Rosa Coucke, Audrey Chansard, et al. · Journal of Cystic Fibrosis · 6
P062 Impact of the SARS-CoV-2 pandemic on clinical trials in the ECFS-CTN during 2020
2021 · S. Van Koningsbruggen-Rietschel, V. Bulteel, et al. · Journal of Cystic Fibrosis · 1
ePS5.08 “Il faut continuer à poser des questions/We must continue to ask questions.” Patient-reported outcomes in cystic fibrosis: a qualitative study of patients with cystic fibrosis and their caregivers
2020 · K. Hayes, I. Sermet, et al. · Journal of Cystic Fibrosis · 1
PDF
WS18.4 Intestinal current measurement as outcome marker for clinical trials: the ECFS CTN certification process and central reading core facility
2016 · S. Scheinert, H. de Jonge, et al. · Journal of Cystic Fibrosis · 1
PDF
P205 Patient-reported outcome measures in the current context of new generation modulator therapies in cystic fibrosis
2021 · K. Hayes, E. Lammertyn, et al. · Journal of Cystic Fibrosis
PDF
European Cystic Fibrosis Society Clinical Trials Network (ECFS-CTN): structure and impact since 2009
2020 · Silke Van Koningsbruggen-Rietschel, Damian G. Downey, et al. · European Respiratory Journal
WS04.4 Guidance on the use of sputum biomarkers to monitor treatment response and act as trial outcomes in cystic fibrosis
2020 · A. Lepissier, C. Addy, et al. · Journal of Cystic Fibrosis
PDF
ePS5.01 Patient reported outcome measures used in clinical practice: an ECFS CTN and CF Europe survey
2020 · K. Hayes, E. Lammertyn, et al. · Journal of Cystic Fibrosis
PDF
A Qualitative Study of Patients With Cystic Fibrosis and Their Caregivers
2020 · Hayes, Kate; id_orcid 0000-0001-5561-8893, Sermet-Gaudelus, Isabelle, et al. · Research Portal (Queen's University Belfast)
P252 When doctors go to patients: a patient-based evaluation of the CFQ
2018 · R. Coucke, V. Bontemps, et al. · Journal of Cystic Fibrosis
PDF
Works count: 19
Citation count: 313
H-index: 9
I10-index: 8
Year
Topic
Type